Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial
Research in Pharmaceutical Sciences · 2024-11 · 19 (6) · 656-668
DOI: 10.4103/rps.rps_274_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 15.12.2024. Verfasst von Alexander Archakov und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Chemistry, Moscow, Russia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background and purpose: Combined hyperlipidemia is associated with an increased risk of cardiovascular events. This clinical trial investigated phospholipovit (essential phospholipids, Institute of Biomedical Chemistry, Moscow, Russia), an ultra-small phospholipid nanoparticle (micelles), targeted to phospholipids of HDL in lowering non-HDL-cholesterol (non-HDL-C) and triglycerides (TG) levels in patients with combined hyperlipidemia and moderate cardiovascular risk. Experimental approach: A randomized, double-blinded, placebo-controlled phase II trial was conducted on 100 patients. Phospholipovit or placebo was randomly administered orally (500 mg) 2 times a day for 12 weeks. The primary endpoint was the percent change of non-HDL-C from baseline to 12 weeks of exposure. Findings/Results: Treatment with phospholipovit resulted in a mean non-HDL-C reduction of 13.2% versus 4.3% compared with placebo. The absolute decrease in non-HDL-C was -23.2 (-48.7 - 7.0) mg/dL versus -7.3 (-17.0 - 12.0) mg/dL, significantly. The therapeutic target of non-HDL-C less than 130 mg/dL (3.4 mmol) was achieved in 15 of 39 patients (38.5%) in the phospholipovit group versus 2 of 41 patients (4.9%) in the placebo group OR 11.8 (2.4 - 116). Significant reduction in TG, apolipoprotein B, total cholesterol, and very low-density lipoprotein cholesterol levels was also observed. There were no changes in the liver and kidney functions, vital signs, or electrocardiography. There were no serious adverse events. Conclusion and implications: Phospholipovit significantly reduced non-HDL-C, TG, and atherogenic lipoproteins in patients with combined hyperlipidemia and moderate cardiovascular risk. It can be used as an add-on therapy to statins.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biomedical Chemistry, Moscow, Russia.
- National Medical Research Center of Cardiology named after Academician E.I. Chazov, Moscow, Russia.
- Department of Probability Theory, Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, Moscow, Russia.
Zitieren
APA
Archakov, A., Kukharchuk, V., Lisitsa, A., Ponomarenko, E., Romashova, Y., Pleshakova, T., Yarovaya, E., Kutsenko, V., Guseva, M., Beregovykh, V., Ipatova, O., Zubareva, M., Tikhonova, E., Ivanov, S., Bedretdinov, F., & Markin, S. (2024). Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial. Research in Pharmaceutical Sciences, 19(6), 656-668. https://doi.org/10.4103/rps.rps_274_23
Vancouver
Archakov A, Kukharchuk V, Lisitsa A, Ponomarenko E, Romashova Y, Pleshakova T, et al. Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial. Research in Pharmaceutical Sciences. 2024;19(6):656-668. doi:10.4103/rps.rps_274_23
BibTeX
@article{Archakov2024,
author = {Archakov, Alexander and Kukharchuk, Valery and Lisitsa, Andrey and Ponomarenko, Elena and Romashova, Yulia and Pleshakova, Tatiana and Yarovaya, Elena and Kutsenko, Vladimir and Guseva, Maria and Beregovykh, Valery and Ipatova, Olga and Zubareva, Marina and Tikhonova, Elena and Ivanov, Sergei and Bedretdinov, Farid and Markin, Sergey},
title = {Ultra-small phospholipid nanoparticles in the treatment of combined hyperlipidemia: a randomized placebo-controlled clinical trial},
journal = {Research in Pharmaceutical Sciences},
year = {2024},
volume = {19},
number = {6},
pages = {656--668},
doi = {10.4103/rps.rps_274_23}
}
EUVIMED